

PIPE JC111
DEC 01 2003
PAVING
RECEIVED

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

1 of 3

Application Number	09/853,033
Filing Date	05/11/2001
First Named Inventor	Pierre Chambon
Group Art Unit	1636
Examiner Name	Celine X. Qian
Attorney Docket Number	065691-0222

[illegible][illegible]

6111/04

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	09/853,033
Date Submitted: December 1, 2003		Filing Date	05/11/2001
Use as many sheets as necessary)		First Named Inventor	Pierre Chambon
2 of 3		Group Art Unit	1636
		Examiner Name	Celine X. Qian
		Attorney Docket Number	065691-0222

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
CA	A11	INDRA A. et al., Temporally-controlled site-specific mutagenesis in the basal layer of the epidermis: comparison of the recombinase activity of the tamoxifen-inducible Cre-ER(T) and Cre-ER(T2) recombinases, Nucleic Acids Research, Nov. 15, 1999, pp. 4324-4327, Vol. 27, No. 22, Oxford University Press, Surrey, GB	
	A12	VASIOUKHIN V. et al., The magical touch: Genome targeting in epidermal stem cells induced by tamoxifen application to mouse skin, Proceedings of the National Academy of Sciences of USA, July 20, 1999, pp. 8551-8556, Vol. 96, No. 15	
	A13	RAGHAVAN S. et al., Conditional ablation of beta1 integrin in skin. Severe defects in epidermal proliferation, basement membrane formation, and hair follicle invagination, The Journal of Cell Biology, Sept. 4, 2000, pp. 1149-1160, Vol. 150, No. 5	
	A14	FENG X. et al., Suprabasal expression of a dominant-negative RXR alpha mutant in transgenic mouse epidermis impairs regulation of gene transcription and basal keratinocyte proliferation by RAR-selective retinoids, Genes & Development, 1997, pp. 59-71, Vol. 11, No. 1	
	A15	SALTOU M. et al., Inhibition of skin development by targeted expression of a dominant-negative retinoic acid receptor, Nature, March 9, 1995, pp. 159-162, Vol. 374, MacMillan Journals Ltd., London, GB	
	A16	LI M. et al., Skin abnormalities generated by temporally controlled RXRalpha mutations in mouse epidermis, Nature, Oct. 5, 2000, pp. 633-636, Vol. 407, No. 6804.	
	A17	KASTNER P. et al., Vitamin A deficiency and mutations of RXRalpha, RXRbeta and RARalpha lead to early differentiation of embryonic ventricular cardiomyocytes, Development, Dec. 1997, pp. 4749-4758, Vol. 124, No. 23	
	A18	SUMI-ICHINOSE C. et al., SNF2beta-BRG1 is essential for the viability of F9 murine embryonal carcinoma cells, Mol. Cell Biol., Oct. 1997, pp. 5976-5986, Vol. 17, No. 10	
	A19	FEIL R. et al., Regulation of Cre recombinase activity by mutated estrogen receptor ligand-binding domains, Biochemical and Biophysical Research Communications, Aug. 28, 1997, pp. 752-757, Vol. 237, No. 3	
	A20	METZGER D. et al., Conditional site-specific recombination in mammalian cells using a ligand-dependent chimeric Cre recombinase, Proceedings of the National Academy of Sciences of USA, July 18, 1995, pp. 6991-6995, Vol. 92, No. 15, National Academy of Science, Washington, USA	
	A21	METZGER D. et al., Engineering the mouse genome by site-specific recombination, Current Opinion in Biotechnology, Oct. 1999, pp. 470-476, Vol. 10, No. 5, London, GB	
	A22	BARLOW C. et al., Targeted expression of Cre recombinase to adipose tissue of transgenic mice directs adipose-specific excision of loxP-flanked gene segments, Nucleic Acids Research, 1997, pp. 2543-2545, Vol. 25, No. 12	

Examiner Signature	Date Considered
	6/11/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: December 1, 2003 (use as many sheets as necessary) Sheet 3 of 3		Complete if Known Application Number 09/853,033 Filing Date 05/11/2001 First Named Inventor Pierre Chambon Group Art Unit 1636 Examiner Name Celine X. Qian Attorney Docket Number 065691-0222	
--	--	---	--

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
CR	A23	IMAI T. et al., Impaired adipogenesis and lipolysis in the mouse upon selective ablation of the retinoid X receptor alpha mediated by a tamoxifen-inducible chimeric Cre recombinase (Cre-ERT2) in adipocytes, Proceedings of the National Academy of Sciences of USA, Jan. 2, 2001, pp. 224-228, Vol. 98, No. 1, USA	
	A24	IMAI T. et al., Inducible site-specific somatic mutagenesis in mouse hepatocytes, Genesis, Feb. 2000, pp. 147-148, No. 2, Wiley-Liss, New York, NY, US	
	A25	WAN Y. et al., Hepatocyte-specific mutation establishes retinoid X receptor alpha as a heterodimeric integrator of multiple physiological processes in the liver, Mol. Cell Biol., June 2000, pp. 4436-4444, Vol. 20, No. 12	
CR	A26	MAHFOUDI A. et al., Specific mutations in the estrogen receptor change the properties of antiestrogens to full agonists, Proceedings of the National Academy of Sciences of the United States, 1995, pp. 4208-4210, Vol. 92, No. 10	

Examiner Signature		Date Considered	6/11/04
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.